Antibody Name: 60.3 (IgG2a SGII | k VkIII)
References: Hsiao, K-c., Bajorath, J. and Harris, L.J. "Humanization of 60.3, an anti-CD18 antibody; importance of the L2 loop" Prot. Engng. (1994) 7:815-822.
Donor Antibody: mouse
Acceptor Antibody: Human IgG1 | k
Antigen: CD18 (component of B2-subunit of leukocyte integrins (eg LFA-1, Mac-1, P150,95)). See also 1B4
Laboratory: Bristol-Myers Squibb, WA
Design: Modelled mouse and humanised V regions, superposed them and systematically compared them on a residue-by-residue basis.
Frameworks: Human VH MO30 | VL Vg
CDRs: All 6 VH and VL, Kabat Definition except reversions CDR-H2 KD64-65QG and CDR-L2 S56T
Backmutations: VH none
VL G68R V104L
Binding: ~4-fold decrease on mouse and chimaeric as measured in FACS assay of binding to HL-60 cells.
Expression: Mouse myeloma Ag8.653
Comment: Tested canonical 71:H but no effect on binding. R50:L in CDR-L2 was important for binding.
Clinical Indication: prevention of neutrophil-associated damage during haemorrhagic shock or reperfusion injury (myocardial infarction).

explanation of symbols and abbreviations

José Saldanha © 1997-8. Birkbeck College, London WC1E 7HX.